183 related articles for article (PubMed ID: 9222071)
21. Comparative antimicrobial activity of trovafloxacin tested against 3049 Streptococcus pneumoniae isolates from the 1997-1998 respiratory infection season.
Jones RN; Pfaller MA; Doern GV
Diagn Microbiol Infect Dis; 1998 Oct; 32(2):119-26. PubMed ID: 9823536
[TBL] [Abstract][Full Text] [Related]
22. Comparative antimicrobial activity of gatifloxacin with ciprofloxacin and beta-lactams against gram-positive bacteria.
Bassetti M; Dembry LM; Farrel PA; Callan DA; Andriole VT
Diagn Microbiol Infect Dis; 2001 Nov; 41(3):143-8. PubMed ID: 11750168
[TBL] [Abstract][Full Text] [Related]
23. The in-vitro activity of trovafloxacin and nine other antimicrobials against 413 anaerobic bacteria.
Bowker KE; Wootton M; Holt HA; Reeves DS; MacGowan AP
J Antimicrob Chemother; 1996 Aug; 38(2):271-81. PubMed ID: 8877542
[TBL] [Abstract][Full Text] [Related]
24. Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.
Harnett SJ; Fraise AP; Andrews JM; Jevons G; Brenwald NP; Wise R
J Antimicrob Chemother; 2004 May; 53(5):783-92. PubMed ID: 15056651
[TBL] [Abstract][Full Text] [Related]
25. The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.
Wise R; Brenwald NP; Andrews JM; Boswell F
J Antimicrob Chemother; 1997 Apr; 39(4):447-52. PubMed ID: 9145816
[TBL] [Abstract][Full Text] [Related]
26. In vitro activity of the combination of trovafloxacin and other antibiotics against enterococci.
Schick DG; Canawati HN; Montgomerie JZ
Diagn Microbiol Infect Dis; 1997 Dec; 29(4):233-9. PubMed ID: 9458980
[TBL] [Abstract][Full Text] [Related]
27. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
Hoogkamp-Korstanje JA
J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of gemifloxacin (SB-265805, LB20304a): in vitro activity against over 6000 gram-positive pathogens from diverse geographic areas.
Jones RN; Pfaller MA; Erwin ME
Int J Antimicrob Agents; 2000 Aug; 15(3):227-30. PubMed ID: 10926446
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique.
Stearne LE; Kooi C; Goessens WH; Bakker-Woudenberg IA; Gyssens IC
Antimicrob Agents Chemother; 2001 Jan; 45(1):243-51. PubMed ID: 11120973
[TBL] [Abstract][Full Text] [Related]
30. Comparative in vitro activity of gemifloxacin.
King A; May J; French G; Phillips I
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():1-12. PubMed ID: 10824026
[TBL] [Abstract][Full Text] [Related]
31. Comparative in vitro activity of CI934, a new fluoroquinolone, alone and in combination with coumermycin, against gram-positive bacteria.
van der Auwera P; Vandermies A; Grenier P; Klastersky J
Drugs Exp Clin Res; 1987; 13(3):125-32. PubMed ID: 3622241
[TBL] [Abstract][Full Text] [Related]
32. In vitro activities of six fluoroquinolones against Canadian isolates of vancomycin-sensitive and vancomycin-resistant Enterococcus species.
Zhanel GG; Karlowsky JA; Hoban DJ
Diagn Microbiol Infect Dis; 1998 Jun; 31(2):343-7. PubMed ID: 9635908
[TBL] [Abstract][Full Text] [Related]
33. Resistance to vancomycin, LY333328, ciprofloxacin and trovafloxacin of community-acquired and nosocomial strains of Enterococcus faecalis isolated in Badajoz (Spain) with and without high-level resistance to streptomycin and gentamicin.
Sánchez-Silos RM; Pérez-Giraldo C; Blanco MT; Morán FJ; Hurtado C; Gómez-García AC
Chemotherapy; 2001 Dec; 47(6):415-20. PubMed ID: 11786656
[TBL] [Abstract][Full Text] [Related]
34. In vitro activity of sparfloxacin (AT-4140 and CI-978), a new quinolone antimicrobial agent, against Haemophilus and gram-positive cocci.
Rudrik JT; Ferrigno SR; Gee SL
Diagn Microbiol Infect Dis; 1991; 14(4):355-60. PubMed ID: 1889186
[TBL] [Abstract][Full Text] [Related]
35. [In vitro activity of six fluoroquinolones and penicillin against 101 viridans group streptococci characterized by their susceptibility to erythromycin].
Rodríguez-Avial I; Rodríguez-Avial C; Picazo JJ
Rev Esp Quimioter; 2001 Dec; 14(4):364-8. PubMed ID: 11856983
[TBL] [Abstract][Full Text] [Related]
36. In vitro activity of trovafloxacin against ciprofloxacin-susceptible and -resistant clinical bacterial isolates and assessment of the trovafloxacin disk test.
Fuchs PC; Barry AL; Brown SD
Diagn Microbiol Infect Dis; 1999 Jan; 33(1):33-8. PubMed ID: 9990473
[TBL] [Abstract][Full Text] [Related]
37. In vitro susceptibility of recent gram-positive isolates to ciprofloxacin, levofloxacin, and trovafloxacin.
Isenberg HD; Alperstein P; France K
Diagn Microbiol Infect Dis; 1998 Oct; 32(2):115-8. PubMed ID: 9823535
[TBL] [Abstract][Full Text] [Related]
38. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.
Nilius AM; Shen LL; Hensey-Rudloff D; Almer LS; Beyer JM; Balli DJ; Cai Y; Flamm RK
Antimicrob Agents Chemother; 2003 Oct; 47(10):3260-9. PubMed ID: 14506039
[TBL] [Abstract][Full Text] [Related]
39. Activity of trovafloxacin (with or without ampicillin-sulbactam) against enterococci in an in vitro dynamic model of infection.
Zinner SH; Gilbert D; Dudley MN
Antimicrob Agents Chemother; 1998 Jan; 42(1):72-7. PubMed ID: 9449263
[TBL] [Abstract][Full Text] [Related]
40. Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae.
Thomson KS; Chartrand SA; Sanders CC; Block SL
Antimicrob Agents Chemother; 1997 Feb; 41(2):478-80. PubMed ID: 9021213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
